Ono Pharmaceutical Co., Ltd.

Japon


 
Quantité totale PI 427
Rang # Quantité totale PI 3 013
Note d'activité PI 3,1/5.0    231
Rang # Activité PI 3 031
Symbole boursier
ISIN JP3197600004
Capitalisation 1507358014200.0  (JPY)
Industrie Drug Manufacturers—General
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

168 13
32 1
200 11
2
 
Dernier brevet 2025 - Eye drop containing sepetaprost
Premier brevet 1976 - 5-fluorouracil derivatives
Dernière marque 2024 - VELEXBRU
Première marque 2004 - ONO

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 P/S Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic ...
Invention Bicyclic compound and use thereof for medical purposes. Since a compound represented by the gene...
Invention Dp antagonist. An object of the present invention is to provide a DP receptor antagonist. A comp...
Invention Sting agonistic compound. A drug or agent containing a compound having an agonistic activity to ...
Invention Eye drop containing sepetaprost. The purpose of the present invention is to provide a sepetaprost...
P/S Pharmaceutical preparations; pharmaceutical substances; anti-cancer preparations; chemical prepar...
P/S Pharmaceutical preparations; pharmaceutical substances; anti-cancer preparations; chemical prepa...
Invention Hla/cancer antigen pvt1-derived peptide complex-specific antibody. The present invention addresse...
Invention Inspection system, inspection method, and program. Provided are an inspection system, an inspecti...
Invention Compounds having s1p5 receptor agonistic activity. A compound represented by the general formula...
Invention + channels) channel function. Disclosed is a compound of formula (I), wherein all symbols are def...
Invention Bispecific antibody. A bispecific antibody which is capable of specifically binding to PD-1 and ...
Invention Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies. Collapsin Response M...
Invention Substituted cyclopenta[c]pyrroles as abhd6 antagonists. A drug is provided, which contains, as a...
Invention Antibody preparation. The problem addressed by the present invention is to provide a novel prepar...
Invention Tricyclic compound. To provide a compound having EP3 agonist activity. A compound represented by ...
Invention Prophylactic and/or therapeutic agent for kidney diseases containing tricyclic compound. Provided...
Invention Gba1 and gcs dual modulator. A compound represented by formula (I) or a pharmaceutically acceptab...
2023 Invention Purinone derivative hydrochloride. The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrr...
Invention Composition for increasing sperm count and/or sperm concentration. Provided is a composition for ...
Invention Therapeutic agent for solid cancers, which comprises axl inhibitor as active ingredient. A thera...
Invention Information processing device, program, and information processing method. [Problem] To provide a...
Invention Abhd6 antagonist. The purpose of the present invention is to provide a drug for the prevention an...
Invention Substituted cyclopenta[c]pyrroles as abhd6 antagonists. A drug is provided, which containing, as ...
Invention Compound having inhibitory activity against diacylglycerol kinase α and/or ζ, and pharmaceutical ...
Invention Bispecific antibody. The present invention addresses the problem of providing a novel drug for pr...
Invention Her2 targeting agent. An antibody or antigen-binding fragment thereof is disclosed. The antibody ...
Invention Purinone derivative. Compounds represented by general formula (I) (all of the symbols in the for...
Invention Chimeric antigen receptor for tumor targeting. Provided are chimeric antigen receptors (CAR) spec...
Invention Sting agonistic compound. A drug or agent containing a compound having an agonistic activity to S...
Invention Single nucleotide polymorphism haplotype analysis method in human sting1 gene. The problem addres...
Invention Compound having kdm5 inhibitory activity and pharmaceutical use thereof. Disclosed are compounds ...
P/S Anti-cancer preparations; chemical preparations for sanitary purposes; chemical preparations for ...
Invention Composition for ophthalmic use containing sepetaprost. The purpose of the present invention is to...
P/S Chemicals for use in the manufacture of pharmaceuticals; chemicals for use in the manufacture of...
Invention Immunity enhancing agent for cancer by allergin-1 antagonist. A method for suppression of progre...
Invention Novel compound, α-synuclein aggregate binder, and use thereof. Provided is a compound that has hi...
Invention Bicyclic compound and use thereof for medical purposes. Since a compound represented by the gener...
Invention Monoclonal antibodies to programmed death 1 (pd-1). The present invention provides isolated mono...
Invention Cancer treatment agent including malt1 inhibiting drug as active ingredient. The combination of a...
Invention Hmgn partial peptide and cancer therapy using the same. Disclosed are a novel therapeutic means e...
2022 Invention Agent for suppressing post-surgical cancer recurrence and/or metastasis. A suppression of postsu...
Invention Gcl inhibitor. Provided is a compound having a GCL inhibitory activity. A compound represented by...
Invention Process for making an ep4 antagonist. The present disclosure provides the methods for making 4-[...
Invention Cancer treatment method by combined use of cd47 inhibitory substance, immune checkpoint inhibitor...
2021 Invention Her2 targeting agent. An antibody that binds to HER2 expressed on a cancer cell or a fragment of...
Invention Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor. The object of...
Invention Prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis. A prophylactic and/or t...
Invention Novel compound, a-synuclein aggregate binder, and use thereof. An embodiment of the present inve...
Invention Tablet comprising opicapone. The present invention provides a tablet comprising opicapone or a p...
Invention Agent for protecting and/or regenerating neuromuscular junction. New uses of an FF-MAS metabolis...
2020 Invention Inhibitors of trek (twik related k+ channels) channel function. Disclosed is a compound of formu...
Invention Modulators of trek (twik related k+ channels) channel function. Disclosed is a compound of formu...
P/S venture capital financing; venture capital fund management; venture capital advisory services; pr...
Invention Sting agonistic compound. The object of the present invention is to provide a drug containing a ...
2018 P/S Pharmaceutical preparations; pharmaceutical preparations for the treatment of liver, digestive, r...
P/S Pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical pre...
P/S Pharmaceutical preparations.
P/S Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal pre...
2017 P/S Organizing, arranging and conduction of educational seminars; educational services. Testing, insp...
2015 P/S Pharmaceuticals. Printed publication; pamphlets in the field of medical science and medication; ...
2004 P/S Medical research for all pharmaceuticals and medicines Medical testing services